12.Baxter
Revenue: $11,362,000,000*
Deerfield, Ill.
2019 rank: 12
R&D spend: $595,000,000
Employees: 50,000
*Fiscal year ended 12/31/2019
Baxter saw its sales tick up 2% year-over-year during the first nine months of 2020. Lower rates of hospitalizations and surgeries during the pandemic have had a negative effect, most notable for the company’s medication delivery and pharmaceuticals businesses. Baxter, though, is also playing a crucial role because of the need for kidney dialysis machines and infusion pumps to treat critically ill COVID-19 patients. “Baxter’s third-quarter performance reflects ongoing demand for our medically essential products as well as the company’s agility and resilience amid a historic public health crisis,” Baxter CEO José Almeida said in an October news release. “Our multiyear transformation has positioned us with the strength and adaptability to address today’s unique challenges while continuing to identify opportunities to drive additional value for patients, clinicians, communities and shareholders.” Baxter early this year acquired the Seprafilm Adhesion Barrier and its assets from Sanofi in a deal worth $350 million. – CN
Key personnel: Joe Almeida, president & CEO; Giuseppe Accogli, SVP & president, Americas and global business units; Laura Angelini, GM, renal care; David Bondi, chief procurement officer; Wil Boren, president, advanced surgery; James Borzi, SVP, chief supply chain officer; Ellen Bradford, SVP & corporate secretary; Gavin Campbell, GM, U.S. renal; Dennis Crowley, SVP, business development & licensing; Stacey Eisen, SVP, global communications & president, Baxter International Foundation; David Ferguson, GM, medication delivery; Cristiano Franzi, SVP & president, EMEA; Andy Frye, SVP & president, APAC; Tobi Karchmer, VP, world medical; Heather Knight, GM, U.S. hospital products; Jacqueline Kunzler, SVP, chief quality officer; Karen Leets, SVP & treasurer; Talvis Love, SVP and CIO; Sean Martin, SVP & general counsel; Jeanne Mason, SVP, human resources; Lynn Pawelski, VP, global regulatory affairs; Sumant Ramachandra, president, pharmaceuticals & SVP, chief science & technology officer; Reaz Rasul, GM, acute therapies; Philippe Reale, VP, planning & fulfillment; David Roman, VP, strategy & financial planning & analysis; Jay Saccaro, EVP & CFO; Joseph Schwan, deputy general counsel, global government policy & reimbursement; Brian Stevens, SVP, chief accounting officer & controller; Clare Trachtman, VP, investor relations; Jorge Vasseur, GM, clinical nutrition; Shirley Xu, GM, Greater China